Pelago Services CETSA® allows the study of target engagement of compounds in a cellular context. But it is the expertise of our target engagement teams that transforms an elegant technology into early insights and actionable data – customized for your purpose, scope and stage in the drug discovery process. That’s why we ensure that our services come with the full support and know-how of a dedicated team with experience from hundreds of drug discovery projects: CETSA® by Pelago Bioscience. Explore, discover and confirm with CETSA® How can we help you? Pelago Bioscience is a specialized CRO, focusing on biologically relevant assays with our patented CETSA® technology as its core. We provide bespoke projects in a wide range of service areas, from target discovery, to lead generation, optimization and confirmation. Our services are based on three flexible product formats that allow our customers to define the scope and value they are looking for: CETSA® Navigate enables rapid target engagement confirmation, CETSA® Navigate HT is for efficient high-throughput discovery, and CETSA® Explore is a Mass Spectrometry-based approach allowing unbiased proteome-wide investigation. CETSA ® TECHNOLOGY Extending beyond our services we offer license agreements enabling you to utilize the CETSA® technology in-house. A single target license can be acquired for a specific target and provides the right to use the specified CETSA® format for that target. In a partnership with PerkinElmer we provide Alpha CETSA® kits, for selected fully validated targets. We have also pre-validated over 40 total AlphaLISA SureFire® Ultra protein kit targets proving that they are amenable to CETSA® . These protein targets are now available as CETSA® ble kits. READ MORE ABOUT ALPHA CETSA ® AND CETSA ® BLE A WIDE RANGE OF SERVICES FROM EARLY DISCOVERY TO CONFIRMATION Our CETSA® teams offer a range of customized services, designed to help you make better decisions faster, no matter where you are in the drug discovery process. True target engagement assessment TARGET IDENTIFICATION LEAD GENERATION LEAD OPTIMIZATION PRECLINICAL STUDIES CLINICAL TRIALS APPROVED DRUGS Explore our knowledge center to discover additional applications for the CETSA® formats. VISIT KNOWLEDGE CENTER ” At AstraZeneca we are applying CETSA® HT in high-throughput screening and lead optimization to identify and characterize hit and lead compounds for a number of novel targets. Thomas Lundbäck Associate director, AstraZeneca Reduce timelines by up to 12 months “Adopting CETSA® can reduce your project timeline by 6-12 months and expedite the progress of compounds from lead generation into the lead optimization stage“ Stina Lundgren, Drug discovery expert, Pelago Bioscience Identifying ECM29 predictive biomarker “It would have been almost impossible to identify the ECM29 predictive biomarker of breast cancer without CETSA® MS“ Teemu P Miettinen, Research fellow, MIT An excellent collaboration partner “I enjoyed very much working with the team at Pelago Bioscience, an excellent collaboration partner. It’s always great to work with such a group of professional people. Thank you“ Margarita Garcia-Calvo, Principal Scientist, Lodo Therapeutics Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery experts CONTACT US BOOK A MEETING Pelago Bioscience AB Banvaktsvägen 20 171 48 Solna Sweden Contact us Privacy Policy We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Pelago Cookies Policy Cookie settings Accept